CRISPR Therapeutics AG (CRSP) Net Income towards Common Stockholders (2015 - 2026)
CRISPR Therapeutics AG (CRSP) reported Net Income towards Common Stockholders of -$122.9 million for Q1 2026, up 9.6% on a YoY basis from -$112.2 million in Q1 2025, and up 24.23% sequentially from -$162.2 million in Q4 2025.
CRISPR Therapeutics AG (CRSP) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$122.9 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 9.6% year-over-year to -$122.9 million; the trailing twelve-month figure through Mar 2026 stood at -$600.2 million (down 3391.11% YoY), and the FY2025 full-year result was -$613.2 million, down 1728.93% from the prior year.
- Net Income towards Common Stockholders advanced to -$122.9 million in Q1 2026, from -$162.2 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $366.6 million in Q4 2024 to a low of -$208.5 million in Q2 2025.
- A 5-year average of -$88.4 million and a median of -$116.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders soared 310.09% in 2024 and sank 144.26% in 2025, its largest moves.
- Tracing CRSP's Net Income towards Common Stockholders over 5 years: stood at -$110.6 million in 2022, then surged by 180.84% to $89.4 million in 2023, then soared by 310.09% to $366.6 million in 2024, then tumbled by 144.26% to -$162.2 million in 2025, then climbed by 24.23% to -$122.9 million in 2026.
- Business Quant data shows CRSP's Net Income towards Common Stockholders at -$122.9 million in Q1 2026, -$162.2 million in Q4 2025, and -$106.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | CRISPR Therapeutics AG | 4.51 Bn | 4.51 Bn | - | -122.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.93 Mn |
| Dec 31, 2025 | -162.25 Mn |
| Sep 30, 2025 | -106.44 Mn |
| Jun 30, 2025 | -208.55 Mn |
| Mar 31, 2025 | -135.99 Mn |
| Dec 31, 2024 | 366.59 Mn |
| Sep 30, 2024 | -85.94 Mn |
| Jun 30, 2024 | -126.42 Mn |
| Mar 31, 2024 | -116.59 Mn |
| Dec 31, 2023 | 89.39 Mn |
| Sep 30, 2023 | -112.14 Mn |
| Jun 30, 2023 | -77.74 Mn |
| Mar 31, 2023 | -53.07 Mn |
| Dec 31, 2022 | -110.58 Mn |
| Sep 30, 2022 | -174.55 Mn |
| Jun 30, 2022 | -185.82 Mn |
| Mar 31, 2022 | -179.22 Mn |
| Dec 31, 2021 | -141.25 Mn |
| Sep 30, 2021 | -127.15 Mn |
| Jun 30, 2021 | 759.23 Mn |